Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59,915 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
S-1-based concurrent chemoradiotherapy plus nimotuzumab in patients with locally advanced esophageal squamous cell carcinoma who failed neoadjuvant therapy: a real-world prospective study.
Wang X, Feng G, Yang X, Yu N, Zheng Z, Li J, Kang X, Chen X, Zhang R, Li Y, Wang Z, Deng L, Zhang T, Liu W, Wang J, Wang W, Feng Q, Xiao Z, Zhou Z, Bi N, Li Y, Qin J. Wang X, et al. Among authors: liu w. Cancer Biol Ther. 2024 Dec 31;25(1):2417464. doi: 10.1080/15384047.2024.2417464. Epub 2024 Oct 27. Cancer Biol Ther. 2024. PMID: 39462770 Free PMC article.
Antiemetic prophylaxis for chemoradiotherapy-induced nausea and vomiting in locally advanced head and neck squamous cell carcinoma: a prospective phase II trial.
Wang Z, Liu W, Zhang J, Chen X, Wang J, Wang K, Qu Y, Huang X, Luo J, Xiao J, Xu G, Gao L, Yi J, Zhang Y. Wang Z, et al. Among authors: liu w. Strahlenther Onkol. 2022 Oct;198(10):949-957. doi: 10.1007/s00066-022-01958-7. Epub 2022 May 30. Strahlenther Onkol. 2022. PMID: 35635557 Free PMC article. Clinical Trial.
Applying post-neoadjuvant pathologic stage as prognostic tool in esophageal squamous cell carcinoma.
Han W, Deng W, Wang Q, Ni W, Li C, Zhou Z, Liang J, Chen D, Feng Q, Bi N, Zhang T, Wang X, Deng L, Wang W, Liu W, Wang J, Xue Q, Mao Y, Liu X, Fang D, Li J, Wang D, Zhao J, Xiao Z. Han W, et al. Among authors: liu x, liu w. Front Oncol. 2022 Nov 10;12:998238. doi: 10.3389/fonc.2022.998238. eCollection 2022. Front Oncol. 2022. PMID: 36439431 Free PMC article.
Induction Immune Checkpoint Inhibitors and Chemotherapy Before Definitive Chemoradiation Therapy for Patients With Bulky Unresectable Stage III Non-Small Cell Lung Cancer.
Wang Y, Zhang T, Wang J, Zhou Z, Liu W, Xiao Z, Deng L, Feng Q, Wang X, Lv J, Ma X, Xue Q, Wang J, Wang Z, Bi N. Wang Y, et al. Among authors: liu w. Int J Radiat Oncol Biol Phys. 2023 Jul 1;116(3):590-600. doi: 10.1016/j.ijrobp.2022.12.042. Epub 2023 Jan 7. Int J Radiat Oncol Biol Phys. 2023. PMID: 36623605
Efficacy and Safety of Concurrent Chemoradiotherapy Combined with Nimotuzumab in Elderly Patients with Esophageal Squamous Cell Carcinoma: A Prospective Real-world Pragmatic Study.
Yu N, Cheng G, Li J, Liang J, Zhang T, Deng L, Liu W, Wang J, Zhai Y, Wang W, Xiao Z, Zhou Z, Chen D, Feng Q, Bi N, Wang X. Yu N, et al. Among authors: liu w. Curr Cancer Drug Targets. 2023;23(8):653-662. doi: 10.2174/1568009623666230315145937. Curr Cancer Drug Targets. 2023. PMID: 36924100 Clinical Trial.
Efficacy and safety of definitive chemoradiotherapy with or without induction immune checkpoint inhibitors in patients with stage III non-small cell lung cancer.
Yang Y, Wang J, Zhang T, Zhou Z, Wang Y, Jiang Y, Liu W, Xiao Z, Deng L, Feng Q, Wang X, Lv J, Wang W, Xue Q, Wang J, Li YX, Bi N. Yang Y, et al. Among authors: liu w. Front Immunol. 2023 Nov 24;14:1281888. doi: 10.3389/fimmu.2023.1281888. eCollection 2023. Front Immunol. 2023. PMID: 38077319 Free PMC article.
Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study).
Wang Y, Deng L, Wang J, Zhang T, Wang W, Wang X, Liu W, Wu Y, Lv J, Feng Q, Zhou Z, Wang J, Wang L, Wang Z, Bi N. Wang Y, et al. Among authors: liu w. Front Immunol. 2024 Jan 15;14:1341584. doi: 10.3389/fimmu.2023.1341584. eCollection 2023. Front Immunol. 2024. PMID: 38288117 Free PMC article.
Effectiveness and safety of combined nimotuzumab and S-1 chemotherapy with concurrent radiotherapy for locally advanced esophageal cancer in malnourished and elderly patients: A prospective phase II study.
Feng G, Li J, Yu N, Zheng Z, Yang X, Deng L, Zhang T, Wang W, Liu W, Wang J, Feng Q, Lyu J, Xiao Z, Zhou Z, Bi N, Qin J, Wang X. Feng G, et al. Among authors: liu w. Chin J Cancer Res. 2024 Jun 30;36(3):270-281. doi: 10.21147/j.issn.1000-9604.2024.03.04. Chin J Cancer Res. 2024. PMID: 38988486 Free PMC article.
59,915 results
You have reached the last available page of results. Please see the User Guide for more information.